Lopixibat Uses, Dosage, Side Effects and more
Lopixibat is under investigation in clinical trial NCT03905330 (A Study to Evaluate the Efficacy and Safety of Lopixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)).
| Trade Name | Lopixibat |
| Availability | Prescription only |
| Generic | Maralixibat |
| Maralixibat Other Names | Lopixibat, Lum-001 cation, Lum001 cation, Maralixibat, Maralixibat cation |
| Related Drugs | Livmarli |
| Type | |
| Formula | C40H56N3O4S |
| Weight | Average: 674.96 Monoisotopic: 674.398604889 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Lopixibat multivitamins interaction
[Moderate] Lopixibat may affect the absorption of fat-soluble vitamins (FSV) including A, D, E, and K.
In a clinical study, emergent FSV deficiency was reported in 10% of patients during 48 weeks of treatment.
In addition, it should be noted that patients with Alagille syndrome (ALGS) can have FSV deficiency at baseline.
Clinical and laboratory monitoring of serum FSV levels is recommended at baseline and during treatment with maralixibat.
If FSV deficiency is diagnosed, supplementation with FSV should be initiated.
If FSV deficiency persists or worsens despite adequate FSV supplementation, discontinuation of maralixibat should be considered.
Disease Interaction
Major: liver diseaseModerate: fat soluble vitamin deficiency
